Tag Archives: CI

Somewhat Positive News Coverage Somewhat Unlikely to Affect Cigna (CI) Stock Price

News headlines about Cigna (NYSE:CI) have trended somewhat positive this week, according to Accern Sentiment Analysis. The research firm identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Cigna earned a news sentiment score of 0.17 on Accern’s scale. Accern also assigned media headlines about the health services provider an impact score of 47.1380454286443 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

These are some of the news stories that may have impacted Accern’s scoring:

Get Cigna alerts:

Moneyism: 4 reasons Americans are lonely (marketwatch.com) Here’s What Wall Street Says About Trump’s Drug Pricing Plan (bloomberg.com) Free Research Report as Anthems EPS Surged 34% (finance.yahoo.com) Even After Earnings Beat, Cigna Corporation Stock Still Looks Stuck (investorplace.com) Cruzan, Cigna Investment Management Acquire 106890 SF Office Building in Beverly Hills (rebusinessonline.com)

CI stock traded up $2.67 on Friday, hitting $173.73. The company’s stock had a trading volume of 2,322,800 shares, compared to its average volume of 2,334,491. The company has a market cap of $41.25 billion, a price-to-earnings ratio of 16.61, a price-to-earnings-growth ratio of 1.04 and a beta of 0.59. The company has a debt-to-equity ratio of 0.37, a current ratio of 0.35 and a quick ratio of 0.35. Cigna has a 1 year low of $158.29 and a 1 year high of $227.13.

Cigna (NYSE:CI) last announced its quarterly earnings data on Thursday, May 3rd. The health services provider reported $4.11 EPS for the quarter, topping the Zacks’ consensus estimate of $3.39 by $0.72. The company had revenue of $11.38 billion during the quarter, compared to the consensus estimate of $10.97 billion. Cigna had a net margin of 5.99% and a return on equity of 20.90%. Cigna’s quarterly revenue was up 8.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.77 EPS. analysts anticipate that Cigna will post 13.23 earnings per share for the current year.

Several brokerages have recently issued reports on CI. Oppenheimer upped their target price on shares of Cigna to $237.00 and gave the company an “outperform” rating in a report on Friday, February 2nd. Morgan Stanley upped their target price on shares of Cigna to $255.00 and gave the company an “overweight” rating in a report on Friday, February 2nd. Barclays began coverage on shares of Cigna in a report on Thursday, March 8th. They issued an “overweight” rating and a $235.00 target price for the company. Credit Suisse Group lowered their target price on shares of Cigna from $232.00 to $215.00 and set an “outperform” rating for the company in a report on Monday, March 12th. Finally, Zacks Investment Research upgraded shares of Cigna from a “sell” rating to a “hold” rating in a research report on Monday, April 16th. Five investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company. Cigna currently has a consensus rating of “Buy” and an average price target of $210.53.

In other Cigna news, insider Christopher J. Hocevar sold 2,759 shares of the company’s stock in a transaction on Monday, March 5th. The shares were sold at an average price of $191.84, for a total transaction of $529,286.56. Following the completion of the transaction, the insider now owns 12,784 shares in the company, valued at approximately $2,452,482.56. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO David Cordani sold 36,769 shares of the company’s stock in a transaction on Monday, March 5th. The stock was sold at an average price of $191.68, for a total transaction of $7,047,881.92. Following the transaction, the chief executive officer now owns 372,076 shares of the company’s stock, valued at approximately $71,319,527.68. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 45,384 shares of company stock valued at $8,693,791. 1.10% of the stock is owned by insiders.

Cigna Company Profile

Cigna Corporation, a health services organization, provides insurance and related products and services in the United States and internationally. It operates through Global Health Care, Global Supplemental Benefits, Group Disability and Life, and Other Operations segments. The Global Health Care segment offers medical, dental, behavioral health, vision, and prescription drug benefit plans, as well as health advocacy programs, and other products and services to insured and self-insured customers.

Insider Buying and Selling by Quarter for Cigna (NYSE:CI)

Somewhat Positive News Coverage Somewhat Unlikely to Affect Cigna (CI) Stock Price

News headlines about Cigna (NYSE:CI) have trended somewhat positive this week, according to Accern Sentiment Analysis. The research firm identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Cigna earned a news sentiment score of 0.17 on Accern’s scale. Accern also assigned media headlines about the health services provider an impact score of 47.1380454286443 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

These are some of the news stories that may have impacted Accern’s scoring:

Get Cigna alerts:

Moneyism: 4 reasons Americans are lonely (marketwatch.com) Here’s What Wall Street Says About Trump’s Drug Pricing Plan (bloomberg.com) Free Research Report as Anthems EPS Surged 34% (finance.yahoo.com) Even After Earnings Beat, Cigna Corporation Stock Still Looks Stuck (investorplace.com) Cruzan, Cigna Investment Management Acquire 106890 SF Office Building in Beverly Hills (rebusinessonline.com)

CI stock traded up $2.67 on Friday, hitting $173.73. The company’s stock had a trading volume of 2,322,800 shares, compared to its average volume of 2,334,491. The company has a market cap of $41.25 billion, a price-to-earnings ratio of 16.61, a price-to-earnings-growth ratio of 1.04 and a beta of 0.59. The company has a debt-to-equity ratio of 0.37, a current ratio of 0.35 and a quick ratio of 0.35. Cigna has a 1 year low of $158.29 and a 1 year high of $227.13.

Cigna (NYSE:CI) last announced its quarterly earnings data on Thursday, May 3rd. The health services provider reported $4.11 EPS for the quarter, topping the Zacks’ consensus estimate of $3.39 by $0.72. The company had revenue of $11.38 billion during the quarter, compared to the consensus estimate of $10.97 billion. Cigna had a net margin of 5.99% and a return on equity of 20.90%. Cigna’s quarterly revenue was up 8.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.77 EPS. analysts anticipate that Cigna will post 13.23 earnings per share for the current year.

Several brokerages have recently issued reports on CI. Oppenheimer upped their target price on shares of Cigna to $237.00 and gave the company an “outperform” rating in a report on Friday, February 2nd. Morgan Stanley upped their target price on shares of Cigna to $255.00 and gave the company an “overweight” rating in a report on Friday, February 2nd. Barclays began coverage on shares of Cigna in a report on Thursday, March 8th. They issued an “overweight” rating and a $235.00 target price for the company. Credit Suisse Group lowered their target price on shares of Cigna from $232.00 to $215.00 and set an “outperform” rating for the company in a report on Monday, March 12th. Finally, Zacks Investment Research upgraded shares of Cigna from a “sell” rating to a “hold” rating in a research report on Monday, April 16th. Five investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company. Cigna currently has a consensus rating of “Buy” and an average price target of $210.53.

In other Cigna news, insider Christopher J. Hocevar sold 2,759 shares of the company’s stock in a transaction on Monday, March 5th. The shares were sold at an average price of $191.84, for a total transaction of $529,286.56. Following the completion of the transaction, the insider now owns 12,784 shares in the company, valued at approximately $2,452,482.56. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO David Cordani sold 36,769 shares of the company’s stock in a transaction on Monday, March 5th. The stock was sold at an average price of $191.68, for a total transaction of $7,047,881.92. Following the transaction, the chief executive officer now owns 372,076 shares of the company’s stock, valued at approximately $71,319,527.68. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 45,384 shares of company stock valued at $8,693,791. 1.10% of the stock is owned by insiders.

Cigna Company Profile

Cigna Corporation, a health services organization, provides insurance and related products and services in the United States and internationally. It operates through Global Health Care, Global Supplemental Benefits, Group Disability and Life, and Other Operations segments. The Global Health Care segment offers medical, dental, behavioral health, vision, and prescription drug benefit plans, as well as health advocacy programs, and other products and services to insured and self-insured customers.

Insider Buying and Selling by Quarter for Cigna (NYSE:CI)